Eligibility and rate of treatment for recombinant tissue plasminogen activator in acute ischemic stroke using different criteria

Academic Emergency Medicine

Volumn 18, Issue 3, 2011, Pages 273-278

  Huang, Poyin ^a   Khor, Gim Thean ^a   Chen, Chun Hung ^a   Lin, Ruey Tay ^a,b   Liu, Ching Kuan ^a,c  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE;

ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CONFIDENCE INTERVAL; DISEASE SEVERITY; DRUG SAFETY; HUMAN; INFORMED CONSENT; MAJOR CLINICAL STUDY; METHODOLOGY; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REFUSAL TO PARTICIPATE; RETROSPECTIVE STUDY; SENESCENCE;

ACUTE DISEASE; ADULT; AGED; BRAIN ISCHEMIA; CHI-SQUARE DISTRIBUTION; COMORBIDITY; ELIGIBILITY DETERMINATION; EMERGENCY SERVICE, HOSPITAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT SELECTION; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; STROKE; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 79952710760     PISSN: 10696563     EISSN: 15532712     Source Type: Journal    
DOI: 10.1111/j.1553-2712.2011.01006.x     Document Type: Article

References (20)

1. Endres M, Engelhardt B, Koistinaho J, et al. Improving outcome after stroke: overcoming the translational roadblock. Cerebrovasc Dis. 2008; 25:268-78. (Pubitemid 351450431)
2. Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology. 2001; 56:1015-20. (Pubitemid 32336306)
3. Weintraub MI. Thrombolysis (tissue plasminogen activator) in stroke: a medicolegal quagmire. Stroke. 2006; 37:1917-22. (Pubitemid 44297752)
4. Kleindorfer D, Kissela B, Schneider A, et al. Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: a population-based study. Stroke. 2004; 35:e27-9.
5. Cocho D, Belvis R, Marti-Fabregas J, et al. Reasons for exclusion from thrombolytic therapy following acute ischemic stroke. Neurology. 2005; 64:719-20. (Pubitemid 40261906)
6. O'Connor RE, McGraw P, Edelsohn L. Thrombolytic therapy for acute ischemic stroke: why the majority of patients remain ineligible for treatment. Ann Emerg Med. 1999; 33:9-14. (Pubitemid 29028774)
7. Katzan IL, Hammer MD, Hixson ED, et al. Utilization of intravenous tissue plasminogen activator for acute ischemic stroke. Arch Neurol. 2004; 61:346-50. (Pubitemid 38327350)
8. de la Ossa NP, Sánchez-Ojanguren J, Palomeras E, et al. Influence of the stroke code activation source on the outcome of acute ischemic stroke patients. Neurology. 2008; 70:1238-43. (Pubitemid 351520963)
9. Huang P, Chen CH, Yang YH, et al. Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: way to endeavor. Cerebrovasc Dis. 2006; 22:423-8. (Pubitemid 44681119)
10. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008; 359:1317-29.
11. Sylaja PN, Cote R, Buchan AM, et al. Thrombolysis in patients older than 80 years with acute ischemic stroke: Canadian Alteplase for Stroke Effectiveness Study. J Neurol Neurosurg Psychiatry. 2006; 77:826-9. (Pubitemid 44023176)
12. Berrouschot J, Röther J, Glahn J, et al. Outcome and severe hemorrhagic complications of intravenous thrombolysis with tissue plasminogen activator in very old (≥80 years) stroke patients. Stroke. 2005; 36:2421-5. (Pubitemid 41566970)
13. Smith EE, Abdullah AR, Petkovska I, et al. Poor outcomes in patients who do not receive intravenous tissue plasminogen activator because of mild or improving ischemic stroke. Stroke. 2005; 36:2497-9. (Pubitemid 41566987)
14. National Institute of Neurological Disorders Stroke rt-PA Stroke Study Group. Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience. Ann Emerg Med. 2005; 46:243-52.
15. Baumann CR, Baumgartner RW, Gandjour J, et al. Good outcomes in ischemic stroke patients treated with intravenous thrombolysis despite regressing neurological symptoms. Stroke. 2006; 37:1332-3. (Pubitemid 43731885)
16. Dirks M, Niessen LW, Koudstaal PJ, et al. Intravenous thrombolysis in acute ischemic stroke: from trial exclusion criteria to clinical contraindication. An international Delphi study. J Neurol Neurosurg Psychiatry. 2007; 78:685-9. (Pubitemid 46998835)
17. Pfefferkorn T, Liebetrau M, Müllner A, Bender A, Hamann GF. Increasing use of intravenous rt-PA does not affect safety in acute stroke. J Neurol. 2005; 252:1500-3. (Pubitemid 41803841)
18. Audebert HJ, Schenkel J, Heuschmann PU, Bogdahn U, Haberl RL, the Telemedic Pilot Project for Integrative Stroke Care Group. Effects of the implementation of a telemedical stroke network: the Telemedic Pilot Project for Integrative Stroke Care (TEMPiS) in Bavaria, Germany. Lancet Neurol. 2006; 5:742-8. (Pubitemid 44205508)
19. Chao AC, Hsu HY, Chung CP, et al. Outcomes of thrombolytic therapy for acute ischemic stroke in Chinese patients. The Taiwan thrombolytic therapy for acute ischemic stroke (TTT-AIS) study. Stroke. 2010; 41:885-90.
20. Ciccone A. Consent to thrombolysis in acute ischaemic stroke: from trial to practice. Lancet Neurol. 2003; 2:375-8. (Pubitemid 38352565)